Effects of Interleukin-3 on Chemotherapy Side Effects
Author Information
Author(s): M.W. Dercksen, K. Hoekman, W.W. ten Bokkel Huinink, E.M. Rankin, R. Dubbelman, H. van Tinteren, J. Wagstaff, H.M. Pinedo
Primary Institution: The Netherlands Cancer Institute/Antoni van Leeuwenhoekhuis
Hypothesis
Can interleukin-3 reduce myelosuppression caused by chemotherapy in ovarian cancer and small cell undifferentiated tumors?
Conclusion
Interleukin-3 has modest effects on reducing chemotherapy-induced neutropenia and thrombocytopenia but can cause significant toxicity when combined with high-dose carboplatin.
Supporting Evidence
- Interleukin-3 reduced the duration of severe neutropenia in patients receiving chemotherapy.
- Patients receiving interleukin-3 experienced more pronounced nausea and vomiting.
- Five out of fifteen patients had to stop interleukin-3 due to severe side effects.
Takeaway
This study looked at whether a drug called interleukin-3 could help people feel better during chemotherapy. It helped a little but also made some people feel worse.
Methodology
Two clinical studies were conducted with patients receiving chemotherapy and interleukin-3, monitoring toxicity and blood cell counts.
Potential Biases
Potential bias due to lack of control groups and subjective reporting of side effects.
Limitations
The studies had a small sample size and were not double-blind.
Participant Demographics
Patients included those with recurrent ovarian carcinoma and small cell undifferentiated tumors, aged less than 70 years.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% confidence interval, 41-90%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website